Summary of the III international consensus symposium on combined antiviral therapy

Antiviral Research

Volumn 38, Issue 2, 1998, Pages 75-93

  Stuart, James W T Cohen ^a   Boucher, Charles A B ^a   Cooper, David A ^e   Galasso, George J ^b   Richman, Douglas D ^c   Thomas, Howard C ^e   Whitley, Richard J ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b The Macrae Group   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

Combination antivirals; Conference summary; Emerging viruses; Hepatitis virus; Herpes viruses; Kaposi sarcoma; Respiratory viruses

Indexed keywords

ACICLOVIR; ADEFOVIR; ADENOSYLHOMOCYSTEINASE; ALPHA INTERFERON; AMANTADINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; HYDROLASE INHIBITOR; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; LAMIVUDINE; LOBUCAVIR; PENCICLOVIR; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RIMANTADINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; SIALIDASE INHIBITOR; UNINDEXED DRUG; VALACICLOVIR; ZANAMIVIR; ZIDOVUDINE;

ANTIMICROBIAL THERAPY; CLINICAL TRIAL; CONDYLOMA; CONFERENCE PAPER; CYTOMEGALOVIRUS; EBOLA VIRUS; FILOVIRIDAE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HERPES SIMPLEX VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHALATIONAL DRUG ADMINISTRATION; INTRALESIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SIDE EFFECT; TOPICAL DRUG ADMINISTRATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; WART VIRUS;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS, VIRAL, HUMAN; HERPESVIRIDAE INFECTIONS; HIV INFECTIONS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIRUS DISEASES;

EID: 0031869389     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00021-7     Document Type: Conference Paper

References (102)

1. Albini A., Barillari G., Benelli R., Gallo R.C., Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc. Natl. Acad. Sci. USA. 92:1995;4838-4842.
2. Anderson, M.G., Harrison, T.J., Alexander, G.J.M., 1986. Randomized trial of lymphoblastoid interferon for chronic active hepatitis B. Br. J. Hepatol. S225-227.
3. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., Katlama C., Debre P., Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
4. Baldanti, F., Underwood, M.R., Stanat, S.C., Biron, K.K., Chou, S., Sarasini, A., Silini, E., Gerna, G., 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70, 1390-1395.
5. Barillari G., Gendelman R., Gallo R.C., Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc. Natl. Acad. Sci. USA. 90:1993;7941-7955.
6. Bartholomew M.M., Jansen R.W., Jeffers L.J., Reddy K.R., Johnson L.C., Bunzendahl H., Condreay L.D., Tzakis A.G., Schiff E.R., Brown N.A. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
7. Benhamou Y., Katlama C., Lunel F., Coutellier A., Dohin E., Hamm N., Tubiana R., Herson S., Poynard T., Opolon P. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann. Intern. Med. 125:1996;705-712.
8. Beutner K.R., Friedman D.J., Forszpaniak C., Andersen P.L., Wood M.J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. 39:1995;1546-1553.
9. Beutner K.R., Ferenczy A. Therapeutic approaches to genital warts. Am. J. Med. 102:1997;28-37.
10. Boivin G., Chou S., Quirk M.R., Erice A., Jordan M.C. Randomised controlled trial of IFNα 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut. 30:1989;1116-1122.
11. Boivin G., Chou S., Quirk M.R., Erice A., Jordan M.C. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173:1996;523-528.
12. Booth, J.C., Brown, J.L., Thomas, H.C., 1995. The management of chronic hepatitis C virus infection . Gut October (37), 449-454.
13. Boppana S.B., Fowler K.B., Vaid Y, Hedlund G., Stagno S., Britt W.J., Pass R.F. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics. 99:1997;409-414.
14. Brillanti, s., Garson, J., Foli, M., Whitby, K., Deaville, R., Masci, C., Miglioli, M., Barbara, L., 1994. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812-817.
15. Brook M.G., Karayiannis P., Thomas H.C. Which patients with chronic hepatitis B infection will respond to IFNα therapy? A statistical analysis of predictive factors. Hepatology. 10:1989;761-763.
16. Carithers R.L. Jr., Emerson S.S. Therapy of hepatitis C: meta-analysis of IFNα-2b trials. Hepatology. 26(3S1):1997;83S-88.
17. Cavert W., Notermans D.W., Staskus K., Wietgrefe S.W., Zupancic M., Gebhard K., Henry K., Zhang Z.Q., Mills R., McDade H., Goudsmit J., Danner S.A., Haase A.T. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 276:1997;960-964.
18. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., Moore P.S. dentification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1994;1865-1869.
19. Charles N.C., Steiner G.C. Ganciclovir intraocular implant. A clinicopathologic study. Ophthalmology. 103:1996;416-421.
20. Chou S., Marousek G., Guentzel S., Follansbee S.E., Poscher M.E., Lalezari J.P., Miner R.C., Drew W.L. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:1997;786-789.
21. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., Kuo Y.H., Brookmeyer R., Zeiger M.A., Barditch-Crovo P., Siliciano R.F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 387:1997;183-188.
22. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science. 267:1995;483-489.
23. Van Cutsem E., Snoeck R., Van Ranst M., Fiten P., Opdenakker G., Geboes K., Janssens J., Rutgeerts P., Vantrappen G., de Clercq E. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Med. Virol. 45:1995;230-235.
24. Delabesse E., Oksenhendler E., Lebbe C., Verola O., Varet B., Turhan A.G. Molecular analysis of clonality in Kaposi's sarcoma. J. Clin. Pathol. 50:1997;664-668.
25. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. New Engl. J. Med. 333:1995;1657-1661.
26. Duker J.S., Robinson M., Anand R., Ashton P. Initial experience with an 8-month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS. Ophthalmic Surg. Lasers. 26:1995;442-448.
27. Emanuel D., Cunningham I., Jules-Elysee K., Brochstein J.A., Kernan N.A., Laver J., Stover D., White D.A., Fels A., Polsky B. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109:1988;777-782.
28. Farrell G.C. Therapy of hepatitis C:IFNα-n1 trials. Hepatology. 26(3S1):1997;96S-100.
29. Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., Quinn, T.C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D.D., Richman, D.D., Siliciano, R., 1997. Identification of a reservoir of HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300.
30. Foster G.R., Goldin R.D., Main J., Murray-Lyon I., Hargreaves S., Thomas H.C. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. Br. Med. J. August 23(315):1997;453-458.
31. Gao S.J., Kingsley L., Li M., Zheng W., Parravicini C., Ziegler J., Newton R., Rinaldo C.R., Saah A., Phair J., Detels R., Chang Y., Moore P.S. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat. Med. 2:1996;925-928.
32. Grossi P., Baldanti F. Treatment of ganciclovir-resistant human cytomegalovirus infection. J. Nephrol. 10:1997;146-151.
33. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., Chodakewitz J.A. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl. J. Med. 337:1997;734-739.
34. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J. Am. Med. Assoc. 275:1996;295-299.
35. Hayden, F.G., Lobo, M., Treanor, J.J., Miller, M., Mills, R.G., 1997. Efficacy and tolerabilty of oral GS4104 for early treatment of experimental influenza in humans. 37th ICAAC, Toronto, Ontario, Canada, September 28-October 1, 1997, Abstract LB-26.
36. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. New Engl. J. Med. 337:1997;874-880.
37. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
38. Huggins J.W., Hsiang C.M., Cosgriff T.M., Guang M.Y., Smith J.I., Wu Z.O., LeDuc J.W., Zheng Z.M., Meegan J.M., Wang Q.N. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164:1991;1119-1127.
39. Huguenel E.D., Cohn D., Dockum D.P., Greve J.M., Fournel M.A., Hammond L., Irwin R., Mahoney J., McClelland A., Muchmore E., Ohlin A.C., Scuderi P. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1. Am. J. Respir. Crit. Care. Med. 155(4):1997;1206-1210.
40. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smythe M.L., White H.F., Oliver S.W. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363(6428):1993;418-423.
41. Jacobson M.A., Zegans M., Pavan P.R., O'Donnell J.J., Sattler F., Rao N., Owens S., Pollard R. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 349(9063):1997;1443-1445.
42. de Jong M.D., Boucher C.A., Galasso G.J., Hirsch M.S., Kern E.R., Lange J.M., Richman D.D. Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases. Antiviral Res. 29:1996;5-29.
43. de Jong M.D., Boucher C.A., Cooper D.A., Galasso G.J., Gazzard B., Lange J.M., Montaner J.S., Richman D.D., Thomas H.C. Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies. Antiviral Res. 35:1997;65-82.
44. Kakumu S., Aiyama T., Okumura A., Iwata K., Ishikawa T., Yoshioka K. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J. Gastroenterol. Hepatol. 12:1997;468-472.
45. Kedes D.H., Operskalski E., Busch M., Kohn R., Flood J., Ganem D. The seroepidemiology of human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat. Med. 2:1996;918-924.
46. Kedes D.H., Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J. Clin. Invest. 99:1997;2082-2086.
47. Kimberlin D.W., Lakeman F.D., Arvin A.M., Prober C.G., Corey L., Powell D.A., Burchett S.K., Jacobs R.F., Starr S.E., Whitley R.J. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J. Infect. Dis. 174:1996;1162-1167.
48. Koelle D.M., Huang M.L., Chandran B., Vieira J., Piepkorn M., Corey L. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J. Infect. Dis. 176:1997;94-102.
49. Lee W.M. Therapy of hepatitis C: IFNα-2a trials. Hepatology. 26(3S1):1997;89S-95.
50. Lefrere J.J., Meyohas M.C., Mariotti M., Meynard J.L., Thauvin M., Frottier J. Detection of human herpesvirus-8 DNA sequences before the appearance of Kaposi's sarcoma in human immunodeficiency virus (HIV)-positive subjects with a known date of HIV seroconversion. J. Infect. Dis. 174:1996;283-287.
51. Lennette E.T., Blackbourn D.J., Levy J.A. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet. 348:1996;858-861.
52. Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., Harrison T.J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
53. Lurain N.S., Spafford L.E., Thompson K.D. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. 68:1994;4427-4431.
54. Mahy W.J. Human viral infections: an expanding frontier. Antiviral Res. 36:1997;75-80.
55. Main, J., Brown, J.L., Howells, C., Galassini, R., Crossey, M., Karayiannis, P., Georgiou, P., Atkinson, G., Thomas, H.C., 1996. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral. Hepat. 3, 211-215.
56. Marcellin P., Boyer N., Colin J.F., Martinot-Peignoux M., Lefort V., Matheron S., Erlinger S., Benhamou J.P. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut. 34(2S):1993;106.
57. Martin D.F., Parks D.J., Mellow S.D., Ferris F.L., Walton R.C., Remaley N.A., Chew E.Y., Ashton P., Davis M.D., Nussenblatt R.B. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol. 112:1994;1531-1539.
58. Marx J.L., Kapusta M.A., Patel S.S., LaBree L.D., Walonker F., Rao N.A., Chong L.P. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch. Ophthalmol. 114:1996;815-820.
59. Monini P., de Lellis L., Fabris M., Rigolin F., Cassai E. Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. New Engl. J. Med. 334:1996;1168-1172.
60. Nevens F., Main J., Honkoop P., Tyrrell D.L., Barber J., Sullivan M.T., Fevery J., De Man R.A., Thomas H.C. Lamivudine therapy for chronic hepatitis B: a 6-month randomized dose-ranging study. Gastroenterology. 113:1997;1258-1263.
61. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., McDade H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA. 93:1996;4398-4402.
62. Okuda H., Nishiyama T., Ogura K., Nagayama S., Ikeda K., Yamaguchi S., Nakamura Y., Kawaguchi Y., Watabe T. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab. Dispos. 25:1997;270-273.
63. Oral Ganciclovir European and Australian Co-operative Study Group, 1995. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 9, 471-477.
64. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science. 271:1996;1582-1586.
65. Pol S., Wesenfelder L., Dubois F., Roingeard P., Carnot F., Driss F., Brechot C., Goudeau A., Berthelot P. Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J. Viral Hepat. 1:1994;131-137.
66. Pollard R.B. CMV retinitis: ganciclovir/monoclonal antibody. Antiviral Res. 29:1996;73-75.
67. Pottage J.C. Jr., Kessler H.A. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect. Agents Dis. 4:1995;115-124.
68. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet. 349:1997;825-832.
69. Reed E.C., Bowden R.A., Dandliker P.S., Lilleby K.E., Meyers J.D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109:1988;783-788.
70. Renne R., Zhong W., Herndier B., McGrath M., Abbey N., Kedes D., Ganem D. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in culture. Nat. Med. 2:1996;342-346.
71. Rossol S., Marinos G., Carucci P., Singer M.V., Williams R., Naoumov N.V. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. 99:1997;3025-3033.
72. Russo JJ., Bohenzky R.A., Chien M.C., Chen J., Yan M., Maddalena D., Parry J.P., Peruzzi D., Edelman I.S., Chang Y., Moore P.S. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. USA. 93:1996;14862-14867.
73. Sanchez A., Trappier S.G., Mahy B.W., Peters C.J., Nichol S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA. 93:1996;3602-3607.
74. Schalm S.W., Fattovich G., Brouwer J.T. Therapy of hepatitis C: patients with cirrhosis. Hepatology. 26(3S1):1997;128S-132.
75. Schalm S.W., Hansen B.E., Chemello L., Bellobuono A., Brouwer J.T., Weiland O., Cavalletto L., Schvarcz R., Ideo G., Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatol. 26:1997;961-966.
76. Schvarcz R., Ando Y., Sonnerborg A., Weiland O. Combination treatment with IFNα-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J. Hepatol. 23(S2):1995;17-21.
77. Smith I.L., Cherrington J.M., Jiles R.E., Fuller M.D., Freeman W.R., Spector S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. Infect. Dis. 176:1997;69-77.
78. Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39:1995;2759-2764.
79. Staskus K.A., Zhong W., Gebhard K., Herndier B., Wang H., Renne R., Beneke J., Pudney J., Anderson D.J., Ganem D., Haase A.T. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71:1997;715-719.
80. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group, 1996. Combination foscarnet and ganciclovir therapy versus monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch. Ophthalmol. 114, 23-33.
81. Sturzl M., Blasig C., Schreier A., Neipel F., Hohenadl C., Cornali E., Ascherl G., Esser S., Brockmeyer N.H., Ekman M., Kaaya E.E., Tschachler E., Biberfeld P. Expression of HHV-8 latency-associated T0.7 RNA in spindle cells and endothelial cells of AIDS-associated, classical and African Kaposi's sarcoma. Int. J. Cancer. 72:1997;68-71.
82. Swinehart J.M., Sperling M., Phillips S., Kraus S., Gordon S., McCarty J.M., Webster G.F., Skinner R., Korey A., Orenberg E.K. Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata. A phase 3 clinical study. Arch. Dermatol. 133:1997;67-73.
83. Thomas G.P., Forsyth M., Penn C.R., McCauley J.W. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res. 24:1994;351-356.
84. Thursz M.R., Kwiatkowski D., Allsopp C.E., Greenwood B.M., Thomas H.C., Hill A.V. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. New Engl. J. Med. 332:1995;1065-1069.
85. Thursz M.R. Host genetic factors influencing the outcome of hepatitis. J. Viral Hepat. 4:1997;215-220.
86. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., Tyrrell D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
87. Turner, R.B., Wecker, M.T., Pohl, G., Witek, T.J., Marlin-McNally, E., Hayden, F.G., 1997. Efficacy of soluble ICAM-1 (sICAM) for prevention of Rhinovirus infection and ilness. 37th ICAAC, Toronto, Ontario, Canada, September 28-October 1, Abstract H-85.
88. Van der Meer J.T., Drew W.L., Bowden R.A., Galasso G.J., Griffiths P.D., Jabs D.A., Katlama C., Spector S.A., Whitley R.J. Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection. Antiviral Res. 32:1996;119-140.
89. Verdonck L.F., de Gast G.C., Dekker A.W., de Weger R.A., Schuurman H.J., Rozenberg-Arska M. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant. 4:1989;187-189.
90. Vieira J., Huang M.L., Koelle D.M., Corey L. Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in saliva of men with a history of Kaposi's sarcoma. J. Virol. 71:1997;7083-7087.
91. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
92. Weiner, L.B., Rotbarth, H.A., Gilbert, D.L., Hayden, F.G., Mynhardt, J.H., Dwyer, D.E., Trocha, H., Rogers, J.M., Mckinlay, M.A., 1997. Treatment of enterovirus meningitis with pleconaril (VP63843), an antipicornaviral agent, 37th ICAAC, Toronto, Ontario, Canada, September 28-October 1, Abstract LB-27.
93. Weller S., Blum M.R., Doucette M., Burnette T., Cederberg D.M., de Miranda P., Smiley M.L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:1993;595-605.
94. Whitley R.J., Weiss H., Gnann J.W. Jr., Tyring S., Mertz G.J., Pappas P.G., Schleupner C.J., Hayden F., Wolf J., Soong S.J. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann. Intern. Med. 125:1996;376-383.
95. Wong D.K., Yim C., Naylor C.D., Chen E., Sherman M., Vas S., Wanless I.R., Read S., Li H., Heathcote E.J. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology. 108:1995;165-171.
96. Wong J.K., Hezareh M., Gunthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
97. Wong J.K., Gunthard H.F., Havlir D.V., Zhang Z., Haase A.T., Ignacio C.C., Kwok S., Emini E., Richman D. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc. Natl. Acad. Sci. USA. 94:1997;12574-12579.
98. Wood, N.D., Aitken, M., Sharp, S., Evison, H., 1997. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers. 37th ICAAC, Toronto, Ontario, Canada, September 28-October 1, Abstract A-123.
99. Woods J.M., Bethell R.C., Coates J.A., Healy N., Hiscox S.A., Pearson B.A., Ryan D.M., Ticehurst J., Tilling J., Walcott S.M. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1993;1473-1479.
100. Yano M., Kumada H., Kage M., Ikeda K., Shimamatsu K., Inoue O., Hashimoto E., Lefkowitch J.H., Ludwig J., Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
101. Zeuzem S., de Man R.A., Honkoop P., Roth W.K., Schalm S.W., Schmidt J.M. Dynamics of hepatitis B virus infection in vivo. J. Hepatol. 27:1997;431-436.
102. Zylberberg H., Jiang J., Pialoux G., Driss F., Carnot F., Dubois F., Brechot C., Berthelot P., Pol S. IFNα for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol. Clin. Biol. 20:1996;968-971.